EU/3/16/1740:

Adeno-associated viral vector serotype 2/2 containing a gene encoding the channelrhodopsin-2 protein

Table of contents

Overview

On 14 October 2016, orphan designation (EU/3/16/1740) was granted by the European Commission to Alacrita LLP, United Kingdom, for adeno-associated viral vector serotype 2/2 containing a gene encoding the channelrhodopsin-2 protein for the treatment of retinitis pigmentosa.

The sponsorship was transferred to Allergan Pharmaceuticals International Limited, Ireland, in September 2017.

Please note that this product was withdrawn from the Union Register of orphan medicinal products in June 2021 on request of the Sponsor.

Key facts

Active substance
Adeno-associated viral vector serotype 2/2 containing a gene encoding the channelrhodopsin-2 protein
Intented use
Treatment of retinitis pigmentosa
Date of designation
14/10/2016
Orphan designation status
Withdrawn
EU designation number
EU/3/16/1740

Sponsor's contact details

Allergan Pharmaceuticals International Limited
Clonshaugh Business and Technology Park 
Coolock
Dublin D17 E400
Ireland
E-mail: medinfo@allergan.com

Patients' organisations

For contact details of patients’ organisations whose activities are targeted at rare diseases, see:

  • European Organisation for Rare Diseases (EURORDIS), a non-governmental alliance of patient organisations and individuals active in the field of rare diseases.

  • Orphanet, a database containing information on rare diseases, which includes a directory of patients’ organisations registered in Europe.

How useful was this page?

Add your rating